Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas

Journal of Endocrinological Investigation

Volumn 27, Issue 4, 2004, Pages 311-317

  Saggiorato, Enrico ^a   Aversa, S ^a   Deandreis, D ^a   Arecco, F ^a   Mussa, A ^a   Puligheddu, B ^a   Cappia, S ^b   Conticello, S ^a   Papotti, M ^a,b   Orlandi, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Fine needle aspiration biopsy; Galectin 3; Lectins; Thyroid diseases; Thyroid neoplasms

Indexed keywords

BIOTIN; GALECTIN 3; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MALE; PREOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SAMPLING; SENSITIVITY ANALYSIS; THYROID ADENOMA; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SURGERY;

EID: 2942597936     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03351054     Document Type: Article

References (48)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993, 328: 553-9.
2. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24: 102-32.
3. Hamming JF, Goslings BM, van Steenis GJ, et al. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med 1990, 150: 113-6.
4. Caraci P, Aversa S, Mussa A, Pancani G, Ondolo C, Conticello S. Role of fine-needle aspiration biopsy and frozen-section evaluation in the surgical management of thyroid nodules. Br J Surg 2002, 89: 797-801.
5. Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol 1993, 9: 345-50.
6. Rosai J, Carcangiu ML, De Lellis RA. Tumors of the thyroid gland. In: Ellis GL and Auclair PL eds. Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology 1992, 49-62.
7. Schlumberger M, Pacini F. Thyroid tumors. Paris: Édtions Nucléon. 1999, 33-42.
8. Saggiorato, E, Cappia S, De Giuli P, et al. Galectin-3 as a pre-surgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001, 86: 5152-8.
9. Ogawa Y, Kato Y, Ikeda K, et al. The value of ultrasound-guided fine-needle aspiration cytology for thyroid nodules: an assessment of its diagnostic potential and pitfalls. Surg Today 2001, 31: 97-101.
10. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002, 87: 1941-6.
11. Harms H, Hofmann M, Ruschenburg I. Fine needle aspiration of the thyroid: can an image processing system improve differentiation? Anal Quant Cytol Histol 2002, 24: 147-53.
12. Tangpricha V, Chen BJ, Swan NC, et al. Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. Thyroid 2001, 11: 973-6.
13. Yang GC, Liebeskind D, Messina AV. Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid? Cancer 2003, 99: 69-74.
14. Serini G, Trusolino L, Saggiorato E, et al. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 1996, 88: 442-9.
15. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin Endocrinol (Oxf) 2002, 56: 281-90.
16. Raphael SJ. The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 2002, 13: 301-11.
17. Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 2003, 191: 223-7.
18. Saji M, Xydas S, Westra WH, et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 1999, 5: 1483-9.
19. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998, 58: 4193-8.
20. van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol 1998, 18: 93-7.
21. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 1997, 10: 668-74.
22. De Micco C, Zoro P, Garcia S, et al. Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy. Eur J Endocrinol 1994, 131: 474-9.
23. Christensen L, Blichert-Toft M, Brandt M, et al. Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clin Endocrinol (Oxf) 2000, 53: 161-9.
24. Lloyd RV. Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocr Pathol 2001, 12: 255-7.
25. Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994, 269: 20807-10.
26. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996, 56: 4530-4.
27. Sato S, Hughes RC. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 1994, 269: 4424-30.
28. Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 1995, 92: 1213-7.
29. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003, 60: 267-76.
30. Takenaka Y, Inohara H, Yoshii T, et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003, 195: 111-9.
31. Raz A., Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 1987, 6: 433-52.
32. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Am J Pathol 1995, 147: 815-22.
33. Fernandez PL, Merino MJ, Gomez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997, 181: 80-6.
34. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58: 3015-20.
35. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357: 1644-50.
36. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 1998, 18: 2637-41.
37. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G. Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 2001, 12: 275-9.
38. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002, 87: 4806-10.
39. Bartolazzi A, Papotti M, Orlandi F. Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. J Clin Endocrinol Metab 2003, 88: 950.
40. Herrmann ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002, 126: 710-3.
41. Kashima K, Yokoyama S, Daa T, Nakayama I, Nickerson PA, Noguchi S. Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. Mod Pathol 1997, 10: 515-9.
42. Niedziela M, Maceluch J, Korman E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab 2002, 87: 4411-5.
43. Bernet VJ, Anderson J, Vaishnav Y, et al. Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2002, 87: 4792-6.
44. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N. Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett 2003, 199: 69-73.
45. Suarez HG. Genetic alterations in human epithelial thyroid tumors. Clin Endocrinol (Oxf) 1998, 48: 531-46.
46. Satta MA, Nanni S, Della Casa S, Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000, 25: 151-61.
47. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003, 162: 1053-60.
48. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88: 2318-26.